Imatinib and type 2 diabetes.

  title={Imatinib and type 2 diabetes.},
  author={David Dingli and Robert C. Wolf and Adrian Vella},
  journal={Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists},
  volume={13 2},
OBJECTIVE To characterize the effect, if any, of imatinib mesylate, an inhibitor of abl tyrosine kinase used in the treatment of chronic myeloid leukemia, on type 2 diabetes. METHODS The centralized pharmacy database was used to identify all patients who had received imatinib at the Mayo Clinic in Rochester, Minnesota, during a 5-year period. The electronic medical records were subsequently reviewed to identify which of these patients had type 2 diabetes. In addition, relevant biochemical… CONTINUE READING